In addition to the efficacy of MSU-42011 in lung cancer, we have previously demonstrated the efficacy of rexinoids in a model of pancreatic ductal adenocarcinoma driven by an activating KrasG12D mutation65 and in the MMTV-Neu model of HER2 + breast cancer53, in which Ras activity is high66–68. This evidence concerns the gene ERBB2 and pancreatic ductal adenocarcinoma.